Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 3:33 PM
Ignite Modification Date: 2025-12-25 @ 1:46 PM
NCT ID: NCT05633992
Description: All participants who received at least 1 dose of study intervention are included.
Frequency Threshold: 5
Time Frame: Up to approximately 30 days
Study: NCT05633992
Study Brief: Safety and Immunogenicity of V116 in Vaccine-naïve Japanese Older Adults (V116-009, STRIDE-9)
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
V116 Participants receive a single intramuscular (IM) injection of V116 on Day 1. 0 None 1 225 77 225 View
PPSV23 Participants receive a single IM injection of PPSV23 on Day 1. 0 None 0 225 96 225 View
Serious Events(If Any):

Serious Events

Term Type Organ System Vocab View
Lacunar infarction SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA Version 26.1 View
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Injection site pain SYSTEMATIC_ASSESSMENT General disorders MedDRA Version 26.1 View
Injection site erythema SYSTEMATIC_ASSESSMENT General disorders MedDRA Version 26.1 View
Fatigue SYSTEMATIC_ASSESSMENT General disorders MedDRA Version 26.1 View
Injection site swelling SYSTEMATIC_ASSESSMENT General disorders MedDRA Version 26.1 View